The highest rate of non-concordant care was seen in patients with cervical cancer.
Roughly half of patients with hematologic cancers or solid tumors lost neutralizing antibody responses to SARS-CoV-2 variants of concern at 6 months after vaccination.
Of the patients studied, 59% demonstrated poor prognostic understanding of curability.
The association between proton pump inhibitors and reduced efficacy of atezolizumab suggest “an urgent need” for evidence on how PPIs might impact other immune checkpoint inhibitors, according to researchers.
ECOG performance status was most strongly associated with death.
Survival outcomes were similar for patients with an extended dosing interval and patients who received standard dosing.
All patients achieved engraftment, and none developed complications associated with COVID-19.
In the platinum-pretreated cohort, the objective response rate was 28%.
RSK4-targeting floxacins could boost the efficacy of chemotherapy.
A single-center, retrospective cohort study was conducted to assess response to treatment and progression of disease in patients with severe lymphopenia undergoing treatment with immune checkpoint inhibitors for NSCLC.
A team of international investigators deployed a survey to understand the needs of patients with EGFR-positive lung cancer community.
Although patient-reported outcomes measures were similar with lorlatinib and crizotinib in non-small cell lung cancer, more patients reported improvement in symptoms with lorlatinib.
The addition of durvalumab after chemoradiotherapy for treatment of stage III NSCLC was cost-effective compared with chemoradiotherapy alone.
Study data presented at the 2020 World Conference on Lung Cancer in Singapore illustrate the utility of a 10-marker methylation panel in lung cancer.
Dean Fennell, MBBS, PhD, presented data from a preliminary analysis of the phase 3 CONFIRM trial at the 2020 World Conference on Lung Cancer in Singapore.
The aim of the phase 3 J-AXEL trial was to confirm nab-paclitaxel’s noninferiority to docetaxel in patients with previously treated non-small cell lung cancer (NSCLC).
Investigators evaluated the safety and feasibility of microcoil in simultaneous localization for multiple pulmonary nodules before video-assisted thoracic surgery (VATS).
This study characterizes the effect of corticosteroid use for immune-related adverse event (irAE) management on survival in patients with non-small cell lung cancer who received immune checkpoint inhibitor therapy.
This retrospective study reviewed small cell transformation (SCT) cases from the past 2 years to investigate the phenomenon of pseudo-SCT.
Overexpression of cannabinoid receptor CB2 may be a prognostic biomarker for NSCLC adenocarcinomas.
Aspirin, metformin, and statins were independently associated with decreased lung cancer mortality, according to a population-based study.
